Markets:

Overview

News

Currencies

International

Treasuries

Evolus, Inc. - Common Stock (NQ:EOLS)

7.355 -0.015 (-0.20%)

Streaming Delayed Price Updated: 2:52 PM EST, Nov 14, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Evolus, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Evolus (EOLS) Q3 2025 Earnings Call Transcript ↗

November 06, 2025

Evolus (EOLS) Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings World Trade

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

November 06, 2025

Via Benzinga

Evolus Reports Third Quarter 2025 Financial Results

November 05, 2025

From Evolus

Via Business Wire

Earnings Scheduled For November 5, 2025 ↗

November 05, 2025

Via Benzinga

Evolus to Participate in 2025 Stifel Healthcare Conference

October 28, 2025

From Evolus

Via Business Wire

Earnings Scheduled For August 5, 2025 ↗

August 05, 2025

Via Benzinga

A Look Ahead: Evolus's Earnings Forecast ↗

August 04, 2025

Via Benzinga

Evolus to Report Third Quarter Financial Results on November 5, 2025

October 22, 2025

From Evolus

Via Business Wire

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 10, 2025

From Evolus

Via Business Wire

Evolus Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 12, 2025

From Evolus

Via Business Wire

Evolus Announces the Appointment of Tatjana Mitchell as Chief Financial Officer

September 08, 2025

From Evolus

Via Business Wire

Evolus Announces Positive Data From Pivotal Trial for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product at 2025 Cosmetic Bootcamp

August 25, 2025

From Evolus

Via Business Wire

Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product

August 20, 2025

From Evolus

Via Business Wire

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 08, 2025

From Evolus

Via Business Wire

What's going on in today's session ↗

August 06, 2025

Looking for insights into the US markets one hour before the close of the markets on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Via Chartmill

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

August 06, 2025

Via Benzinga

Here are the top movers in Wednesday's session. ↗

August 06, 2025

Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report.

Via Chartmill

The market is filled with gapping stocks in Wednesday's session. ↗

August 06, 2025

Traders are paying attention to the gapping stocks in Wednesday's session. Let's dive into which stocks are experiencing notable gaps.

Via Chartmill

Evolus (EOLS) Q2 Revenue Rises 4% ↗

August 06, 2025

Via The Motley Fool

Topics Economy

Discover the top movers in Wednesday's pre-market session. ↗

August 06, 2025

The US market session of Wednesday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.

Via Chartmill

Super Micro Computer Posts Downbeat Q4 Results, Joins Personalis, Snap And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

August 06, 2025

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

August 06, 2025

Via Benzinga

Why Astera Labs Shares Are Trading Higher By Over 17%; Here Are 20 Stocks Moving Premarket ↗

August 06, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

August 05, 2025

Via Benzinga

Top movers in Tuesday's after hours session ↗

August 05, 2025

Let's have a look at what is happening on the US markets after the closing bell on Tuesday. Below you can find the top gainers and losers in today's after hours session.

Via Chartmill

Evolus Reports Second Quarter 2025 Financial Results and Provides Business Updates

August 05, 2025

From Evolus

Via Business Wire

Evolus Announces Publication of Independent Study in JAMA Dermatology Demonstrating Jeuveau® as a Top Performer Among Leading Neurotoxins

July 31, 2025

From Evolus

Via Business Wire

Evolus to Report Second Quarter Financial Results on August 5, 2025

July 22, 2025

From Evolus

Via Business Wire

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 11, 2025

From Evolus

Via Business Wire

Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in France

July 09, 2025

From Evolus

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.